NCT05452772View on ClinicalTrials.gov

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

May 31, 2027

Conditions
Tobacco Use Disorder
Interventions
DRUG

Psilocybin

Participants will received two psilocybin sessions, 1 week apart

DRUG

Niacin

Participants will received two niacin sessions, 1 week apart

Trial Locations (3)

10016

RECRUITING

New York University, New York

21224

RECRUITING

Johns Hopkins University School of Medicine, Baltimore

35294

RECRUITING

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
collaborator

University of Alabama at Birmingham

OTHER

collaborator

New York University

OTHER

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Johns Hopkins University

OTHER